首页> 外文期刊>Health technology assessment: HTA >The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation

【24h】

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation

机译：硼替佐米和沙利度胺联合烷基化剂和皮质类固醇激素联合治疗多发性骨髓瘤的一线治疗的临床疗效和成本效益：系统评价和经济评价

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Health technology assessment: HTA》 |2011年第41期|共页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类放射卫生;
关键词

相似文献

外文文献
中文文献
专利

1. The clinical effectiveness and cost effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: A systematic review and economic evaluation [J] . Health technology assessment: HTA . 2011,第41期

机译：硼替佐米和沙利度胺联合烷化剂和皮质类固醇激素治疗多发性骨髓瘤的一线治疗的临床疗效和成本效益：系统评价和经济评价
2. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model [J] . Health technology assessment: HTA . 2013,第14期

机译：一线化疗后西妥昔单抗（单药或联合化疗），贝伐单抗（与非奥沙利铂化疗联合）和帕尼单抗（单药）治疗转移性结直肠癌的临床疗效和成本效益（技术评估编号第150号技术评估和第118号技术评估的部分复审：系统复审和经济模型
3. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. [J] . Robertson C, Arcot Ragupathy SK, Boachie C, Health technology assessment: HTA . 2011,第34期

机译：原发性乳腺癌治疗后不同的乳房X线摄影方案的临床疗效和成本效益：系统评价注册数据库分析和经济评价。
4. MULTIPLE LITERATURE QUALITY EVALUATION OF SYSTEMATIC REVIEW/META ANALYSIS OF ACUPUNCTURE IN THE TREATMENT OF CERVICAL SPONDYLOSIS BASED ON RADAR PLOT [C] . J.Q-Fang, T.Yu, R.R.Nie, 2012 international conference on system simulation . 2012

机译：基于雷达图的颈椎病治疗系统评价/针灸系统评价的多文献质量评价
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation. [O] . J Picot, K Cooper, J Bryant, -1

机译：一个系统的回顾和经济评价：临床有效性和硼替佐米的成本效益和沙利度胺结合的烷化剂为一线治疗多发性骨髓瘤的皮质类固醇服法。
7. The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation [O] . Picot, J., Cooper, K., Bryant, J., 2011

机译：硼替佐米和沙利度胺联合使用烷化剂和皮质类固醇治疗多发性骨髓瘤一线治疗的临床疗效和成本效益：系统评价和经济评价

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号